Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Grand Pharmaceutical GroupFRA:MX6A +1.80%86 EBITDA Margin % is 3.69% as of Dec. 2025, which is 87% below its 10-year median of 28.99. GuruFocus rates FRA:MX6A with a GF Score™ of 86/100 and a GF Value™ of €0.63 (Modestly Undervalued). The stock has 6 warning signs investors should review. Among 961 Drug Manufacturers companies, Grand Pharmaceutical Group ranks better than 52.45% on this metric.
Grand Pharmaceutical Group (FRA:MX6A) EBITDA Margin % Explanation
EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.
Grand Pharmaceutical Group EBITDA Margin % Related Terms
Grand Pharmaceutical Group EBITDA Margin % Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Grand Pharmaceutical Group's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Grand Pharmaceutical Group EBITDA Margin % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Grand Pharmaceutical Group's EBITDA Margin % distribution charts can be found below:
* The bar in red indicates where Grand Pharmaceutical Group's EBITDA Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Grand Pharmaceutical Group (FRA:MX6A) has a EBITDA Margin % of 3.69% as of Dec. 2025. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Grand Pharmaceutical Group and its competitors. This is 87% below median its historical median of 28.99. Over the past decade, Grand Pharmaceutical Group's EBITDA Margin % has ranged from 13.49 to 38.98. According to the industry distribution chart, Grand Pharmaceutical Group ranks #457 out of 961 companies in the Drug Manufacturers industry, placing it in the top 47.6%.
Is Grand Pharmaceutical Group's EBITDA Margin % too high?
Grand Pharmaceutical Group's current EBITDA Margin % of 3.69% is 87% below median its 10-year median of 28.99. Over the past 10 years, this metric has ranged from a low of 13.49 to a high of 38.98. The Drug Manufacturers industry median EBITDA Margin % is 12.49. Grand Pharmaceutical Group's value of 3.69% is 70.5% below this industry median. Based on the distribution chart, Grand Pharmaceutical Group ranks #457 out of 961 companies in the Drug Manufacturers industry, which is above the industry midpoint. Overall, Grand Pharmaceutical Group has a GF Score™ of 86/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Grand Pharmaceutical Group's EBITDA Margin % compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Grand Pharmaceutical Group ranks #457 out of 961 companies for EBITDA Margin %. This puts Grand Pharmaceutical Group in the upper half of its industry. The industry median EBITDA Margin % is 12.49. Grand Pharmaceutical Group's value of 3.69% is 70.5% below this benchmark. Historically, Grand Pharmaceutical Group's own EBITDA Margin % has ranged from 13.49 to 38.98 over the past decade. While the company's 10-year median is 28.99 vs. the industry median of 12.49, Grand Pharmaceutical Group has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBITDA Margin % for a Drug Manufacturers company?
The median EBITDA Margin % among Drug Manufacturers companies is 12.49, based on 961 companies in the industry. Companies in the top quartile (top 25%) have a EBITDA Margin % significantly above this median, while those in the bottom quartile fall well below. However, EBITDA Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Grand Pharmaceutical Group's current EBITDA Margin % of 3.69% is 70.5% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBITDA Margin % mean?
A high EBITDA Margin % can signal that a stock is expensive relative to its fundamentals. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Grand Pharmaceutical Group and its competitors. For the Drug Manufacturers industry, the median EBITDA Margin % is 12.49 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Grand Pharmaceutical Group's current EBITDA Margin % is 3.69%, which is 87% below median its own 10-year median of 28.99. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Grand Pharmaceutical Group stock overvalued right now?
Based on GuruFocus' analysis, Grand Pharmaceutical Group (FRA:MX6A) is currently considered Modestly Undervalued. The stock's GF Value™ is €0.63, compared to a current price of €0.57 — trading 10.3% below its estimated fair value. The current EBITDA Margin % is 3.69%, which is 87% below median its 10-year median of 28.99 and 70.5% below the Drug Manufacturers industry median of 12.49. Grand Pharmaceutical Group's overall GF Score™ is 86/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBITDA Margin % calculated?
EBITDA Margin % is calculated from a company's financial statements. For Grand Pharmaceutical Group (FRA:MX6A), the current EBITDA Margin % is 3.69% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Grand Pharmaceutical Group (FRA:MX6A) Overvalued in 2026?
Based on GuruFocus' analysis, Grand Pharmaceutical Group stock appears to be undervalued.
The current stock price of €0.57 is trading 10.3% below its estimated GF Value™ of €0.63.
GuruFocus considers Grand Pharmaceutical Group to be Modestly Undervalued.
Key valuation signals for FRA:MX6A:
EBITDA Margin %: 3.69% (87% below median its 10-year median of 28.99)
GF Value™: €0.63 vs. price of €0.57 (10.3% below fair value)
Industry Position: 70.5% below the Drug Manufacturers median (#457 of 961)
No single metric tells the full story. See the FRA:MX6A stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Grand Pharmaceutical Group Ltd are principally engaged in the manufacture and sales of pharmaceutical technology products, manufacture and sales of bio-technology products as well as manufacture and sales of nuclear medicine anti-tumor diagnosis and treatment and cerebro-cardiovascular precision interventional diagnosis and treatment technology products, in the People's Republic of China. The operation of the group constitutes one single reportable segment. The company has presence in The PRC, America, Europe, Asia other than the PRC and Others. The majority of revenue comes from the PRC. Its brands are breathe, biology, Cardiovascular emergency care, Cardiovascular intervention, ENT, tumor.
86GF Score
Get the complete analysis for FRA:MX6A
EBITDA Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:MX6A has been successfully added to your 
